Physician profile
Jordan E Angell
NPI 1306021076
$5,026.31
in general payments reported to CMS, 2019-2025
46 companies · $926 in 2025
The $926 reported for 2025 was more than what a typical Urology provider received nationally (typical 2025 total: $631).
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2019: $801 · 2020: $94.57 · 2021: $635 · 2022: $743 · 2023: $1,022 · 2024: $804 · 2025: $926.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Food and Beverage: $2,710 · Education: $43.26.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Food and Beverage | $2,709.75 |
| Education | $43.26 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Astellas Pharma US INC | $673.37 | 2019-2024 | Myrbetriq, Xtandi |
| Dornier Medtech America, INC | $390.59 | 2023 | Dornier Medtech |
| Pfizer INC. | $366.21 | 2019-2025 | |
| Teleflex LLC | $341.60 | 2021-2025 | Urolift, Barrigel |
| Medtronic, INC. | $287.68 | 2023-2025 | Interstim |
| Janssen Biotech, INC. | $215.91 | 2019-2024 | Akeega, Erleada |
| Urogen Pharma, INC. | $214.08 | 2021-2025 | Jelmyto |
| Antares Pharma, INC. | $201.04 | 2019-2025 | Xyosted, Tlando |
| Dendreon Pharmaceuticals LLC | $188.79 | 2019-2025 | Provenge |
| Coloplast Corp | $182.45 | 2021-2025 | Speedicath, Porges Coloplast |
| Progenics Pharmaceuticals, INC. | $155.69 | 2024-2025 | |
| Novartis Pharmaceuticals Corporation | $146.04 | 2022-2025 | |
| Myriad Genetic Laboratories, INC. | $145.37 | 2021-2023 | Prolaris |
| Endo Pharmaceuticals INC. | $135.09 | 2019-2020 | |
| Myovant Sciences INC. | $128.37 | 2021-2022 |
Show all 44 companies
| Company | General payments | Years | Top products |
|---|---|---|---|
| Sumitomo Pharma America, INC. | $126.04 | 2023-2025 | Orgovyx, Gemtesa |
| Bayer Healthcare Pharmaceuticals INC. | $122.16 | 2019-2025 | |
| Olympus America INC. | $113.54 | 2023-2025 | Itind System, Uretero-Reno Videoscope |
| Abbvie INC. | $77.49 | 2022-2024 | |
| Laborie Medical Technologies Corp. | $74.12 | 2024 | Optilume Bph Drug Coated Balloon Catheter |
| Allergan, INC. | $73.49 | 2019-2022 | |
| Immunitybio, INC. | $67.34 | 2024-2025 | |
| Tempus Ai, INC | $53.05 | 2024-2025 | Xt Cdx |
| Bioprotect Medical, INC. | $50.29 | 2025 | Bioprotect Balloon Implant System |
| Accord Healthcare, INC. | $47.20 | 2025 | |
| Tolmar, INC. | $43.26 | 2023 | |
| Janssen Scientific Affairs, LLC | $42.41 | 2023 | Erleada |
| Tolmar Pharmaceuticals, INC. | $36.88 | 2019-2021 | |
| 180 Medical, INC. | $32.27 | 2023-2025 | Gentlecath Glide |
| Janssen Pharmaceuticals, INC | $30.62 | 2025 | Erleada |
| Procept Biorobotics Corporation | $26.09 | 2019 | |
| Ethicon US, LLC | $24.12 | 2023 | Echelon; Endopath |
| Merck Sharp & Dohme LLC | $23.88 | 2022 | |
| Dentsply Ih INC. | $22.96 | 2022 | |
| Calyxo, INC. | $21.14 | 2025 | Cvac Aspiration System |
| Amgen INC. | $19.93 | 2019 | |
| Avadel Specialty Pharmaceuticals, LLC | $19.13 | 2019 | |
| Neotract INC. | $18.85 | 2019 | |
| Acerus Pharmaceuticals Corporation | $16.12 | 2022 | |
| Srs Medical Systems, INC. | $16.02 | 2019 | |
| Metuchen Pharmaceuticals | $15.35 | 2019 | |
| Verity Pharmaceuticals INC. | $15.35 | 2025 | Trelstar |
| Telix Pharmaceuticals | $13.29 | 2023 | Illuccix |
| Palette Life Sciences, INC. | $11.64 | 2022 |
2 companies reported research payments only; those appear in the research section below.
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
Research and ownership
$361,837.72 in ownership or investment interests, as reported to CMS. These are holdings a clinician or an immediate family member has in a company, not payments received.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Jordan Angell listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.